NeuroNova – A leader in therapeutic neurogenesis
NeuroNova is leading the development of therapeutic neurogenesis. Our drug development projects are aimed at stimulating processes in the brain that lead to the formation of new neurons. We believe therapeutic neurogenesis can revolutionize the treatment of several currently incurable neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s disease, as well as certain orphan drug indications like ALS and Huntington's disease. NeuroNova’s vision is to provide new therapies that will enhance the quality of life of millions of people.
NeuroNova uses its integrated platform of drug discovery technologies for neurogenesis, the Neurogenesis Qualifier, to identify therapeutically relevant drug targets and to develop drugs to these targets. NeuroNova applies its technology to identify new CNS uses for existing drugs, thereby creating new market potential for these drugs, while minimizing both development risk and development time.
NeuroNova has two drug candidates progressing through preclinical development, and further promising compounds in discovery and early preclinical development. NeuroNova is continuously generating new projects to enrich its pipeline.
NeuroNova intends to out-license its drug candidates or partner them with pharmaceutical or biotechnology companies at the preclinical or early clinical proof-of-concept stage. In some cases, NeuroNova may retain full rights to market a product in specific countries.
Founded in 1998 by two leading neuroscientists from Karolinska Institutet, NeuroNova is based in Stockholm, Sweden, and employs 25 full-time staff.
Ulf Ljungberg, PhD – President and Chief Executive Officer
NeuroNova AB
Fiskartorpsvägen 15A-D
S-114 33 Stockholm
Sweden
Fax: +46 8 786 09 11
Email: job@neuronova.com
